Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PSE import final rule published

This article was originally published in The Tan Sheet

Executive Summary

Ephedrine, pseudoephedrine and phenylpropanolamine importers must provide the Drug Enforcement Administration information on foreign distribution chains, according to a final rule under the Combat Methamphetamine Act adopted by DEA. The 1rule, published March 5 in the Federal Register, goes into effect May 4. The act requires DEA to collect information about the suppliers of the chemicals with which U.S. importers, exporters, brokers or traders conduct business and the quantities shipped and the date of shipments. Importers and exporters must use DEA Form 486A, which can be filed electronically, to provide information about import quotas of the chemicals and contact information. While DEA implements tighter oversight of supply chains under the law enacted in 2006, two states moved all PSE products to Rx-only and other states are considering the change (2"The Tan Sheet" Feb. 8, 2010)

You may also be interested in...



Mississippi PSE Prescription Switch Will Not Start An Avalanche - CHPA

Mississippi lawmakers' decision to make all pseudoephedrine-containing drugs prescription-only will not prompt other states combating methamphetamine to do the same, the Consumer Healthcare Products Association predicts

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

China Planning To Ban Gene Editing Technology Exports

Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel